

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.  
Form 6-K  
August 01, 2008

FORM 6-K  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of August 2008

Commission File No. 000-30752

AETERNA ZENTARIS INC.

1405, boul. du Parc-Technologique  
Quebec, Quebec  
Canada, G1P 4P5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F.

Form 20-F /X/ Form 40-F / /  
--- ---

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes / / No /X/  
--- ---

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g3-2(b): 82-

-----

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION

1. Press Release dated July 31, 2008: AEterna Zentaris to Present at Upcoming  
BMO Capital Markets 2008 Focus on Healthcare Conference and 28th Annual  
Canaccord Adams Global Growth Conference

[AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.  
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881  
www.aezsinc.com

PRESS RELEASE  
For immediate release

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

AETERNA ZENTARIS TO PRESENT AT UPCOMING BMO CAPITAL  
MARKETS 2008 FOCUS ON HEALTHCARE CONFERENCE AND 28TH  
ANNUAL CANACCORD ADAMS GLOBAL GROWTH CONFERENCE

QUEBEC CITY, CANADA, JULY 31, 2008 - AETerna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, M.D., will present a company overview at the upcoming BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, 2008 at 1:45 pm (eastern time), in Room 3 of the Millennium Broadway Hotel in New York City.

Furthermore, Professor, Jurgen Engel, Ph.D., Executive Vice President and Chief Scientific Officer at AETerna Zentaris will also present a company overview at the 28th Annual Canaccord Adams Global Growth Conference on Wednesday, August 13, 2008 at 10:00 am (Eastern Time) in the London room of the Intercontinental Hotel in Boston.

A live webcast of Professor Engel's presentation will be available on AETerna Zentaris' website at [www.aezsinc.com](http://www.aezsinc.com) in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

ABOUT AETERNA ZENTARIS INC.

AETerna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at [www.aezsinc.com](http://www.aezsinc.com).

#### INVESTOR RELATIONS

Dennis Turpin, CA  
Senior Vice President and Chief Financial Officer  
(908) 626-5503  
[dturpin@aezsinc.com](mailto:dturpin@aezsinc.com)

#### MEDIA RELATIONS

Paul Burroughs  
Director of Communications  
(418) 652-8525 ext. 406  
[pburroughs@aezsinc.com](mailto:pburroughs@aezsinc.com)

-30-

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: August 1, 2008  
-----

By: /s/Dennis Turpin  
-----

Dennis Turpin  
Senior Vice President, Chief Financial Officer